Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.44 |
| ▸ | VCAM1 | P19320 | 5/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.39 |
| ▸ | TXNRD3 | Q86VQ6 | 1/20 | 0.39 |
| ▸ | TXNRD2 | Q9NNW7 | 1/20 | 0.39 |
| ▸ | CTSB | P07858 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32679322 | 1.00 | TDP1 (0.46) | TDP1MAPK1TSHRATMALDH1A1 | |
| SCHEMBL16972865 | 0.92 | MAPK1 (0.46) | TDP1MAPK1TSHRATMALDH1A1 | |
| SCHEMBL7872533 | 0.85 | TDP1 (0.46) | TDP1MAPK1TSHRATMALDH1A1 | |
| SCHEMBL2477068 | 0.84 | TSHR (0.52) | TDP1MAPK1TSHRATMALDH1A1 | |
| SCHEMBL29653309 | 0.84 | TSHR (0.52) | TDP1MAPK1TSHRATMALDH1A1 | |
| SCHEMBL30434858 | 0.82 | TDP1 (0.50) | TDP1MAPK1TSHRATMALDH1A1 | |
| SCHEMBL8967138 | 0.82 | TDP1 (0.50) | TDP1MAPK1TSHRATMALDH1A1 | |
| SCHEMBL29663529 | 0.82 | ATM (0.55) | TDP1MAPK1ATMALDH1A1CYP3A4 | |
| SCHEMBL9694173 | 0.82 | TSHR (0.50) | TDP1MAPK1TSHRATMALDH1A1 | |
| SCHEMBL7335 | 0.82 | ATM (0.55) | TDP1MAPK1ATMALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024017258-A1 | EGFR SMALL MOLECULE INHIBITOR, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE THEREOF | 百极弘烨(南通)医药科技有限公司 | 2024-01-25 | — | — | WO | disclosed |
| US-11773091-B2 | 6-5 fused rings as C5a inhibitors | CHEMOCENTRYX, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| CN-116670127-A | EGFR inhibitors and compositions and uses thereof | 贝达药业股份有限公司 | 2023-08-29 | — | — | CN | disclosed |
| US-20230151002-A1 | 6-5 FUSED RINGS AS C5a INHIBITORS | CHEMOCENTRYX, INC. | 2023-05-18 | — | — | US | disclosed |
| CN-110997674-B | 6-5 fused rings as C5a inhibitors | 凯莫森特里克斯股份有限公司 | 2022-12-20 | — | — | CN | disclosed |
| WO-2022206797-A1 | EGFR INHIBITOR, AND COMPOSITION AND USE THEREOF | 贝达药业股份有限公司 | 2022-10-06 | — | — | WO | disclosed |
| US-10710978-B2 | STK4 inhibitors for treatment of hematologic malignancies | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-07-14 | — | — | US | disclosed |
| CN-110997674-A | 6-5 fused rings as C5a inhibitors | 凯莫森特里克斯股份有限公司 | 2020-04-10 | — | — | CN | disclosed |
| US-20180111916-A1 | STK4 INHIBITORS FOR TREATMENT OF HEMATOLOGIC MALIGNANCIES | FONDAZIONE CENTRO SAN RAFFAELE (IT) | 2018-04-26 | — | — | US | disclosed |
| US-20180111916-A1 | STK4 INHIBITORS FOR TREATMENT OF HEMATOLOGIC MALIGNANCIES | FONDAZIONE CENTRO SAN RAFFAELE (IT) | 2018-04-26 | — | — | US | disclosed |
| WO-2016161145-A1 | STK4 INHIBITORS FOR TREATMENT OF HEMATOLOGIC MALIGNANCIES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-10-06 | — | — | WO | disclosed |
| WO-2016161145-A1 | STK4 INHIBITORS FOR TREATMENT OF HEMATOLOGIC MALIGNANCIES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230151002-A1 | 6-5 FUSED RINGS AS C5a INHIBITORS | C5AR1, C5AR2, C3AR1 | TDP1 4383/4885MAPK1 2196/4885TSHR 766/4885 |
| US-11773091-B2 | 6-5 fused rings as C5a inhibitors | C5AR1, C5AR2, C3AR1 | TDP1 4383/4885MAPK1 2196/4885TSHR 766/4885 |
| US-20180111916-A1 | STK4 INHIBITORS FOR TREATMENT OF HEMATOLOGIC MALIGNANCIES | STK4, STK3, STK11 | TDP1 1095/4885MAPK1 341/4885TSHR 3410/4885 |
| US-10710978-B2 | STK4 inhibitors for treatment of hematologic malignancies | STK4, STK3, STK11 | TDP1 1095/4885MAPK1 341/4885TSHR 3410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.